Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clindamycin Hydrochloride

FDA-approved product (capsule, oral), marketed as Cleocin, Cleocin Hydrochloride, Clindamycin Hydrochloride.

Registered studies
50+
Lab records
4
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Clindamycin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Bacterial disease
  • Endometritis
  • Infection
  • Osteomyelitis
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives for treatment of acne; Antibiotics; Lincosamides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D10AF01; WHO ATC J01FF01; WHO ATC G01AA10

Repurposing investigation

Clindamycin Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis4.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 0 of 4 lab records
Open Clindamycin Hydrochloride in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clindamycin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)

    NCT07421804 · start 2026-04

    Registered record
    Registry ID
    NCT07421804
    Conditions
    Acne Vulgaris
    Interventions
    topical dutasteride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-04
    Completion
    2028-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    Interventiontopical dutasteride
    PhaseNot applicable
    Registry statusNot yet recruiting

  • The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment

    NCT06925386 · start 2025-05-01

    Registered record
    Registry ID
    NCT06925386
    Conditions
    Acne Vulgaris
    Interventions
    Standard therapy; HEXBIO; Secretome
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-05-01
    Completion
    2026-05-01
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionStandard therapy; HEXBIO; Secretome
    PhasePhase 2
    Registry statusNot yet recruiting

  • Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery

    NCT06207786 · start 2024-09-01

    Registered record
    Registry ID
    NCT06207786
    Conditions
    Skin Cancer; Skin Cancer Face; Malignant Cutaneous Adnexal Neoplasm
    Interventions
    Povidone-Iodine Swabs; Staphylococcus nasal swab; Antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2024-09-01
    Completion
    2030-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Cancer; Skin Cancer Face; Malignant Cutaneous Adnexal Neoplasm
    InterventionPovidone-Iodine Swabs; Staphylococcus nasal swab; Antibiotic
    PhaseNot applicable
    Registry statusWithdrawn

  • Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

    NCT06494072 · start 2024-08-22

    Registered record
    Registry ID
    NCT06494072
    Conditions
    Community Acquired Pneumonia in Children
    Interventions
    Ampicillin for Injection; Ceftriaxone for Injection; Amoxicillin; Ampicillin / Sulbactam Injection; Amoxicillin-clavulanate; Clindamycin; Cefprozil; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-22
    Completion
    2028-05
    Enrolment
    236

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity Acquired Pneumonia in Children
    InterventionAmpicillin for Injection; Ceftriaxone for Injection; Amoxicillin; Ampicillin / Sulbactam Injection +4 more
    PhasePhase 4
    Registry statusRecruiting

  • Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia

    NCT06336824 · start 2024-06-28

    Registered record
    Registry ID
    NCT06336824
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid; IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-06-28
    Completion
    2025-06
    Enrolment
    290

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionTab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid; IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
    PhasePhase 3
    Registry statusUnknown

  • Effect of Intracanal Medicaments on Post-Operative Pain in Symptomatic Apical Periodontitis: An RCT

    NCT07123792 · start 2024-06-03

    Registered record
    Registry ID
    NCT07123792
    Conditions
    Periodontal Diseases
    Interventions
    Calcium Hydroxide (20%); Chlorhexidine Gel (2%); Modified Triple Antibiotic Paste
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-06-03
    Completion
    2025-06-03
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriodontal Diseases
    InterventionCalcium Hydroxide (20%); Chlorhexidine Gel (2%); Modified Triple Antibiotic Paste
    PhaseNot applicable
    Registry statusCompleted

  • Clinical and Radiographic Evaluation of Zinc Oxide-Propolis Mixture Versus Modified Triple Antibiotic Paste in LSTR

    NCT06158451 · start 2024-03-01

    Registered record
    Registry ID
    NCT06158451
    Conditions
    Pain, Postoperative; Periapical; Infection
    Interventions
    Zinc oxide propolis; Modified triple antibiotic paste
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-03-01
    Completion
    2025-01-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain, Postoperative; Periapical; Infection
    InterventionZinc oxide propolis; Modified triple antibiotic paste
    PhaseNot applicable
    Registry statusUnknown

  • CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

    NCT05846399 · start 2023-09-07

    Registered record
    Registry ID
    NCT05846399
    Conditions
    Cat Bite; Hand Injuries; Arm Injury; Infection, Bacterial; Anti-bacterial Agents
    Interventions
    Amoxicillin/clavulanate; Ciprofloxacin; Clindamycin; Placebo (microcrystalline cellulose); Wound management
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-09-07
    Completion
    2027-08-01
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCat Bite; Hand Injuries; Arm Injury; Infection, Bacterial +1 more
    InterventionAmoxicillin/clavulanate; Ciprofloxacin; Clindamycin; Placebo (microcrystalline cellulose) +1 more
    PhasePhase 4
    Registry statusRecruiting

  • Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University Hospitals

    NCT06291181 · start 2023-01-01

    Registered record
    Registry ID
    NCT06291181
    Conditions
    Staphylococcus Aureus
    Interventions
    antibiotic sensitivity test
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-01-01
    Completion
    2023-06-30
    Enrolment
    265

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus
    Interventionantibiotic sensitivity test
    PhaseNot applicable
    Registry statusCompleted

  • Staphylococcus Aureus Network Adaptive Platform Trial

    NCT05137119 · start 2022-02-16

    Registered record
    Registry ID
    NCT05137119
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Cefazolin; Penicillin; Clindamycin; Vancomycin; Effectiveness of early switch to oral antibiotics; Whole body FDG PET/CT Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-02-16
    Completion
    2028-12-01
    Enrolment
    8,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionCefazolin; Penicillin; Clindamycin; Vancomycin +2 more
    PhasePhase 4
    Registry statusRecruiting

  • Detection of Clindamycin Resistance Antibiotic Genes Among Staphylococcus Isolates by Using Real Time PCR

    NCT04933019 · start 2021-07-01

    Registered record
    Registry ID
    NCT04933019
    Conditions
    Staphylococcus Isolates
    Interventions
    Detection of Clinclidamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2021-07-01
    Completion
    2022-08-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Isolates
    InterventionDetection of Clinclidamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR
    PhaseEarly phase 1
    Registry statusUnknown

  • The Effect of Prophylactic Antibiotics on Surgical Site Infection Lower Limb Skin Excisions

    NCT03357419 · start 2021-03

    Registered record
    Registry ID
    NCT03357419
    Conditions
    Skin Lesion
    Interventions
    Cephalexin; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2021-03
    Completion
    2022-03-27
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Lesion
    InterventionCephalexin; Placebo oral capsule
    PhaseNot applicable
    Registry statusWithdrawn

  • Bactiseal Catheter Safety Registry in China

    NCT04496414 · start 2020-09-01

    Registered record
    Registry ID
    NCT04496414
    Conditions
    Hydrocephalus
    Interventions
    Bactiseal Catheter
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-09-01
    Completion
    2020-11-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHydrocephalus
    InterventionBactiseal Catheter
    PhaseNot recorded
    Registry statusCompleted

  • Intra-wound Vancomycin Powder for Prevention of Surgical Site Infection Following Spinal Surgery

    NCT05959603 · start 2020-05-31

    Registered record
    Registry ID
    NCT05959603
    Conditions
    Infection
    Interventions
    Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2020-05-31
    Completion
    2026-12-01
    Enrolment
    363

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    InterventionVancomycin
    PhasePhase 3
    Registry statusRecruiting

  • Antibiotic Prophylaxis in Rhinoplasty

    NCT04194216 · start 2020-05-20

    Registered record
    Registry ID
    NCT04194216
    Conditions
    Nasal Obstruction; Nasal Surgical Procedures
    Interventions
    Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.; Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Enrolling by invitation
    Start
    2020-05-20
    Completion
    2027-04-20
    Enrolment
    864

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasal Obstruction; Nasal Surgical Procedures
    InterventionIntra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.; Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days
    PhasePhase 3
    Registry statusEnrolling by invitation